{"id":"NCT01878292","sponsor":"Forest Laboratories","briefTitle":"Safety and Efficacy of Vilazodone in Adolescent Patients With Major Depressive Disorder","officialTitle":"A Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Vilazodone in Adolescent Patients With Major Depressive Disorder","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-07-11","primaryCompletion":"2016-03-17","completion":"2016-10-05","firstPosted":"2013-06-14","resultsPosted":"2019-12-24","lastUpdate":"2019-12-24"},"enrollment":529,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Major Depressive Disorder"],"interventions":[{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Vilazodone","otherNames":["Viibryd"]},{"type":"DRUG","name":"Vilazodone","otherNames":["Viibryd"]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Vilazodone 15 mg","type":"EXPERIMENTAL"},{"label":"vilazodone 30 mg","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the efficacy, safety, and tolerability of vilazodone relative to placebo in adolescent outpatients (12-17) with major depressive disorder.","primaryOutcome":{"measure":"Change in Children's Depression Rating Scale - Revised (CDRS-R) Total Score","timeFrame":"From Baseline to week 8","effectByArm":[{"arm":"Placebo","deltaMin":-22.48,"sd":0.921},{"arm":"Vilazodone 15 mg","deltaMin":-22.94,"sd":0.904},{"arm":"Vilazodone 30 mg","deltaMin":-24.22,"sd":0.872}],"pValues":[]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":4},"locations":{"siteCount":52,"countries":["United States"]},"refs":{"pmids":["29633166"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":171},"commonTop":["Nausea","Headache","Abdominal pain upper","Diarrhoea","Vomiting"]}}